Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010 Dec 1;52(6):1906-14. doi: 10.1002/hep.23947
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the 9th Canadian Immunization Conference; December 2010. Previously presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Karve S, Misurski D, Miller JM, Davis KL. Long-term economic and clinical burden of complicated invasive meningococcal disease: evidence from a United States managed care population. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A432.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010 Oct 1;52(4):1193-200.
Davis KL, Misurski DA, Miller JD, Karve SJ. Impact of invasive meningococcal disease-related complications on health care utilization and costs. Poster presented at the 48th Annual Meeting of the Infectious Diseases Society of America; October 2010.
Karve SJ, Misurski DA, Herrera-Taracena G, Davis KL. Health care utilization and costs associated with influenza-related complications: findings from a large United States managed care population. Poster presented at the 48th Annual Meeting of the Infectious Diseases Society of America; October 2010.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2010.
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.
Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Rousculp M, Gilligan T, Hollis KA, Griffin J, Price MA, Thompson M. Elementary school-based influenza vaccination programs: findings to inform pandemic vaccination campaigns. Poster presented at the Pediatric Academic Society Annual Meeting; May 2010. Previously presented at the 44th Annual National Immunization Conference.
Rousculp M, Gilligan T, Hollis KA, Price MA, Thompson M, Williams VS. Elementary school-located influenza vaccination programs: findings to inform pandemic vaccination campaigns. Poster presented at the Annual Meeting of the Pediatric Academic Societies; May 2010.
Rousculp M, Gilligan T, Hollis KA, Griffin J, Price MA, Thompson M. Elementary school-based influenza vaccination programs: findings to inform pandemic vaccination campaigns. Poster presented at the 44th Annual National Immunization Conference; April 2010.
Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.
Huang H, Huang Z, Coulomb S, Lafuma A, Arana A. A drug utilization study of posaconazole in French hospitals. Presented at the 26th International Conference on Pharmacoepidemiology; 2010.
Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prev Med. 2009 Nov 1;37(5):381-8.
Smets E, Stoll M, Hill A, Soorapanth S, Donatz V, Brogan AJ. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 12th European AIDS Conference/EACS; November 2009.
Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.
Smets E, Soorapanth S, Brogan AJ, Mrus J. Cost-efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Bapat BS, Bell TJ, Candrilli SD. Estimates of the indirect burden of invasive meningococcal disease: insight from public health officials. Poster presented at the 47th Annual Meeting of the Infectious Diseases Society of America; October 2009.
Knoll S, Jochum D, Talbird SE. Cost-utility analysis of pneumococcal conjugate vaccines in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A429.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Lasry A, Sansom S, Hicks KA, Uzunangelov VJ. A model for allocating HIV prevention resources in the United States. Poster presented at the National HIV Prevention Conference; August 2009.
Poulos C, Levin C, Hoang V, Yang J, Nguyen D. Mothers' and fathers' private demand for HPV vaccines in Viet Nam. Poster presented at the 7th World Congress on Health Economics: Harmonizing Health and Economics; July 2009.
Bischof M, Brogan AJ, Talbird SE, Cavassini M, Bernasconi E, Furrer H. Cost-effectiveness of the first-line antiretroviral backbone therapies in combination with efavirenz in HIV-infected patients in Switzerland. Poster presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2009. Cape Town, South Africa.
Strutton DR, Kuchenbecker U, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009.
Stoykova B, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in the United Kingdom (UK). Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009. Brussels, Belgium.
Soorapanth S, Brogan AJ, Mrus J, Smets E. Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 2009. [abstract] Value Health. 12(3):A112.
Rivera R, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination versus 7-valent pneumococcoal conjugate vaccination in Mexico. Poster presented at el Pediátrica XIII Congreso Latinoamericano de Infectología Pediátrica; May 2009.
Hernandez JD, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination compared to 7-valent pneumococcal conjugate vaccination in Colombia. Poster presented at La Sociedad Latinoamericana de Infectología Pediátrica XIII Congreso Latinoamericano de Infectología; May 2009.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine in treatment naïve adults with HIV infection in the United States. Poster presented at the 21st Annual Meeting and Showcase of the American Managed Care Pharmacy; April 2009.
Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009 Mar 4;27(10):1609-21.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.
Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M, Poulos C, Boral S, Nyamete A, Deen J, Ochiai L, Bhattacharya SK. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 2009 Feb 1;37(2):399-409.
Mast C, DeMuro-Mercon CJ, Kelly C, Floyd LE, Walter E. The impact of rotavirus gastroenteritis on the family. BMC Pediatr. 2009 Feb;9(11).
Brogan AJ, Soorapanth S, Donatz V, Hill A, Smets E. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. Paris, France. [abstract] Value Health. 2009; 12(7):A426.
Brown DS, Johnson FR, Poulos C, Messonier MM. Mother-daughter preferences & willingness to pay for HPV vaccination. Presented at the 2nd Vaccine Global Congress; December 2008.
Mitra D, Candrilli SD. Inpatient costs and outcomes associated with hepatitis c, human immunodeficiency virus, and co-infection with both in the United States. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 8, 2008. [abstract] Value Health. 2008 Nov; 11(6):A440-1.
Brogan AJ, Everhard F, Talbird SE, Hutt E. Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the United States. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Brogan AJ, Everhard F, Talbird SE, Hutt E, Zimovetz E. NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluation. Poster presented at the 9th International Congress on Drug Therapy in HIV Infection; November 2008.
Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Economic burden of hcv and hiv co-infection compared to hcv alone in a managed care population. Poster presented at the Joint Meeting of the American Society for Microbiology and Infectious Disease Society of America; October 2008.
Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin. 2008 Oct;24(10):2821-8.
Davis KL, Bapat BS, Bell TJ, Miller JD. Hospital costs, length of stay, and mortality associated with meningococcal disease in the United States. Poster presented at the 2008 Infectious Disease Society of America (IDSA) Annual Meeting; October 2008.
Farkouh RA, Earnshaw SR, Watson ME, Maroudos P. Short-term cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Disease Society of America 46th Annual Meeting; October 2008.
Brogan AJ, Mauskopf JA, Martin S, Smets E. Cost-effectiveness of darunavir for treatment experienced adults with HIV infection in the US. Poster presented at the Annual Meeting of the Institute for Operations Research and Management Science; October 2008.
Hicks KA, Uzunangelov VJ, Lasry A, Sansom S. Allocating CDC's HIV prevention funds. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Hicks KA, Richter A. Impact of uncertainty in hiv resource allocation. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Whittington D, Suraratdecha C, Poulos C, Ainsworth M, Prabhu V, Tangcharoensathien V. Household demand for preventive HIV/AIDS vaccines in Thailand: do husbands' and wives' preferences differ? Value Health. 2008 Sep 1;11(5):965-74.